Piezo1 is a cation channel that opens when the cell membrane is stretched, converting mechanical force into calcium signaling. Because it sits at the interface of membrane tension, extracellular matrix state, calcium influx, reactive oxygen species signaling, and cellular remodeling, the authors argue it is well positioned to mediate the responses of ocular tissues to sustained mechanical load. Both high myopia, marked by axial elongation, posterior-segment stretch, and scleral remodeling, and glaucoma, driven by intraocular pressure-related outflow stress, optic nerve head strain, and vulnerable retinal ganglion cells, converge on chronic mechanical stress acting on compartment-specific weak points in the eye.

The review grades the evidence by ocular compartment, and the grades differ sharply. There, multiple lines of investigation converge: channel activation and perturbation experiments, calcium signaling measurements, matrix and prostaglandin readouts, and assays of outflow function all point to Piezo1 as a functional mechanotransducer in this tissue. Findings in retinal ganglion cells, the neurons that die in glaucoma, are described as emerging.

In the myopia context, the current data support retinal or posterior-segment stress signaling more strongly than a specific causal role for scleral fibroblasts in extracellular matrix remodeling, the process thought to drive the thinning and weakening of the sclera in highly myopic eyes. Two areas remain explicitly exploratory: Piezo1 evidence specific to scleral fibroblasts in myopia, and evidence from the peripapillary sclera, the ring of sclera surrounding the optic nerve head that transmits mechanical load to the nerve. These are precisely the compartments that a full myopia-to-glaucoma axis would need to traverse, which is why the authors frame their proposal as a scaffold for future experiments rather than a conclusion.

The central caveat is stated bluntly. Current evidence does not demonstrate a continuous, Piezo1-dependent causal chain running from scleral remodeling or peripapillary load redistribution to optic nerve head deformation and subsequent degeneration of retinal ganglion cells. This evidence-graded approach is the review's methodological contribution.

Rather than treating all mechanotransduction findings as equivalent, the authors separate directly supported tissue-level mechanisms from cross-compartment relationships that require targeted validation. That distinction matters for experimental design: studies in trabecular meshwork cells can build on a solid foundation, whereas claims about scleral fibroblasts or peripapillary biomechanics will need purpose-built models before they can be considered established. The authors are careful, however, to distinguish such a susceptibility framework from proof of causation.

For now, the review's practical output is a map of what is known, what is moderately supported, and what remains speculative. The trabecular meshwork stands on firm ground, the optic nerve head occupies an intermediate position, and the myopia-side compartments await decisive experiments.

Subject of Research: Piezo1 mechanotransduction as a hypothesized mechanobiological link between high myopia and glaucoma

Article Title: Piezo1 mechanobiology in high myopia and glaucoma: compartment-specific evidence, gaps, and a hypothesis-generating susceptibility framework

Article References: Zhao, C., Chen, G., Wang, C., Chen, H., & Shi, J. (2026). Piezo1 mechanobiology in high myopia and glaucoma: compartment-specific evidence, gaps, and a hypothesis-generating susceptibility framework. Frontiers in Bioengineering and Biotechnology, 14, 1925939. https://doi.org/10.3389/fbioe.2026.1925939

Image Credits: AI Generated

DOI: 10.3389/fbioe.2026.1925939

Keywords: Piezo1, high myopia, glaucoma, mechanotransduction, ocular biomechanics, trabecular meshwork, scleral remodeling, retinal ganglion cells, optic nerve head, intraocular pressure, calcium signaling, review article

The research team, led by Anyi Zhang, Luca Masin, and Lieve Moons of KU Leuven together with collaborators in Paris, used a transgenic zebrafish line that sparsely labels individual retinal ganglion cells with a fluorescent membrane marker, making it possible to trace the full dendritic tree of single neurons in the adult retina. By combining this imaging approach with optic nerve crush injury, quantitative morphometrics, transcriptomic analysis, and pharmacological manipulation, they mapped how dendritic architecture changes as axons regenerate, and identified the molecular switch that governs the process.

The first surprise came from the anatomy. After optic nerve crush, the dendrites of retinal ganglion cells did not remain intact while their axons regrew. Instead, by three days post-injury the cells had lost roughly thirty percent of their total dendritic length and branch points, and by six days, when axons were just beginning to re-enter the brain, the number of bifurcations had fallen to around sixty percent of uninjured levels. Crucially, the overall footprint of the dendritic field was largely preserved, indicating that the remodeling involved the selective elimination of terminal branches rather than wholesale collapse of the arbor. As the axons re-established connections with the optic tectum, the brain’s visual processing center, dendritic complexity rebounded, approaching uninjured architecture by twenty-one days after injury.

This transient simplification was not random degeneration. Gene set enrichment analysis of a bulk RNA sequencing dataset from isolated adult zebrafish retinal ganglion cells showed that transcripts associated with synapses, dendrites, and synaptic transmission were coordinately downregulated between one and six days post-injury, precisely the window in which axons are extending through the optic nerve. The same window saw a sweeping suppression of the insulin-PI3K-Akt-mTOR cascade, the signaling pathway long regarded as a master regulator of cellular growth and a major target of regenerative medicine. Receptor and adapter components such as insra, irs1, and irs2a declined, as did regulatory PI3K subunits and key nodes of the mTOR machinery including rptor, rictor, rheb, and tsc genes.

Because RNA levels are an imperfect proxy for pathway activity, the researchers also examined protein phosphorylation in retinal tissue. They used antibodies against phosphorylated ribosomal protein S6, a well-established readout of mTORC1 activity, the growth-controlling complex downstream of Akt. The results revealed a striking biphasic pattern. In the first two days after injury, the fraction of S6-phosphorylated cells in the ganglion cell layer surged, reaching roughly fifty percent for the Ser235/236 site and up to eighty-five percent for the Ser240/244 site, suggesting an early burst of mTORC1 activity that likely helps initiate the regenerative program. Then, from day three onward, the signal collapsed to near-undetectable levels, coinciding exactly with the onset of dendritic pruning and sustained axonal elongation.

The team also tested whether Gsk3β, a kinase previously implicated in dendrite pruning, was driving the remodeling. Although total Gsk3β protein increased after injury, its inhibitory Ser9 phosphorylation rose even more, indicating a net reduction in kinase activity. The pruning program, in other words, was associated primarily with the repression of mTORC1 signaling rather than with activation of the destructive kinase, sharpening the causal picture.

The decisive experiment came from pharmacology. When the researchers injected recombinant human insulin into the eye on days two through four after injury, they kept the mTOR pathway active during the window when it would normally be suppressed. Insulin treatment did exactly what the model predicted: it partially preserved dendritic complexity, with treated retinal ganglion cells retaining greater dendritic length, area, and branching at six days post-injury. But the preserved dendrites came at a cost. Anterograde tracing with biocytin showed that insulin-treated fish reinnervated their optic tectum roughly fifty percent less than vehicle-treated controls, a clear delay in axonal regrowth. Keeping the dendrites intact, it seemed, actively hindered the rebuilding of the axon.

Follow-up experiments confirmed that this effect runs through mTORC1. Rapamycin, a selective mTORC1 inhibitor, reversed the dendritic preservation caused by insulin, restoring dendritic metrics to vehicle levels. Conversely, MHY1485, a small-molecule mTOR activator, mimicked insulin: it increased dendritic complexity, including more than a fifty percent rise in branch points, and likewise delayed tectal reinnervation by about half. Together, these results establish that mTORC1-dependent maintenance of dendritic branching is a limiting factor for sustained axonal regrowth in the regenerating zebrafish visual system.

Why would a neuron sacrifice its input structures to rebuild its output? The authors propose a resource-allocation model. In mature mammalian neurons, mitochondria become locked near synapses and recycling endosomes are confined to the somatodendritic compartment, whereas regenerating zebrafish retinal ganglion cells transiently relocate mitochondria from dendrites into elongating axons. Insulin receptors sit at the postsynaptic density and mTOR is enriched in dendrites, where it drives local protein synthesis. By pruning dendrites and repressing dendritic mTOR signaling, the neuron may free up protein synthesis capacity, membrane material, and metabolic energy, redirecting these limited resources toward the growing axon. The sequence also echoes development: in both fish and mice, retinal ganglion cells extend their axons first and only elaborate dendrites after the axon has reached its brain target, suggesting that the adult regenerative program recapitulates an ancient developmental order to avoid competition between the two compartments.

The findings carry an uncomfortable implication for mammalian regenerative medicine. Strategies that hyperactivate mTOR, such as PTEN deletion, reliably induce robust axonal regrowth in injured mouse optic nerves, yet extensive functional reinnervation of central brain targets remains largely unachieved. The zebrafish data raise the possibility that sustained mTOR activity may itself hinder the later phases of repair, and that precisely timed, biphasic control of the pathway, an early burst to initiate regeneration followed by deliberate suppression to permit dendritic remodeling and resource reallocation, could be the missing ingredient. Translating that temporal logic to the mammalian central nervous system will be challenging, and the authors caution that their study relied on pharmacological tools rather than genetic perturbation, did not examine contributions from microglia or Müller glia, and leaves open how dendritic pruning affects the electrical activity of regenerating neurons. Still, the message from the fish is clear and provocative: sometimes the best way to rebuild a nerve is to let part of the cell go first.

Subject of Research: Dendritic pruning and mTORC1 signaling regulation during optic nerve regeneration in adult zebrafish retinal ganglion cells

Article Title: Repressed mTORC1 signaling and transient dendritic pruning support axonal regeneration in adult zebrafish

Article References: Zhang, A., Masin, L., Bergmans, S., Putti, E., Albadri, S., Poulain, F. E., Del Bene, F., & Moons, L. (2026). Repressed mTORC1 signaling and transient dendritic pruning support axonal regeneration in adult zebrafish. iScience, 29(11), Article 117826. https://doi.org/10.1016/j.isci.2026.117826

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117826

Keywords: zebrafish, optic nerve regeneration, retinal ganglion cells, dendritic pruning, mTORC1, insulin signaling, axonal regrowth, optic tectum reinnervation, neuroregeneration, PI3K-Akt-mTOR, rapamycin, CNS repair

Retinitis pigmentosa is a group of inherited retinal degenerations that affects more than 1.5 million people worldwide. The disease progressively destroys the retina’s photoreceptors, the rods and cones that normally capture light and convert it into electrical signals for the brain. Patients typically first notice difficulty seeing at night, followed by a narrowing of peripheral vision that worsens over years, ultimately leading to severe vision loss or blindness. Because the retina is part of the central nervous system, its capacity for self-repair is extremely limited, and once photoreceptors are lost they are not naturally replaced.

One of the central obstacles to treating the disease is its sheer genetic diversity. Retinitis pigmentosa can arise from mutations in any one of more than 100 distinct genes, which makes a mutation-by-mutation strategy impractical for most patients. Gene therapies that correct specific defects have succeeded for other blinding conditions, but building and validating a separate treatment for every causative gene is proving tremendously difficult and costly. The Pittsburgh-led team, under the direction of José-Alain Sahel, chair of ophthalmology at Pitt and director of the UPMC Vision Institute, pursued a fundamentally different logic: rather than fixing the underlying mutation, the therapy aims to make surviving retinal cells light-sensitive again, regardless of which gene caused the degeneration.

The technical approach relies on optogenetics, in which cells are genetically altered to produce light-sensing proteins borrowed from other organisms. In this trial, the researchers delivered a gene encoding a protein called ChrimsonR into surviving retinal ganglion cells through a single injection into the eye. Retinal ganglion cells are the output neurons of the retina; in a healthy eye they relay signals from photoreceptors to the brain, and in advanced retinitis pigmentosa many of them remain viable even after the light-sensing cells above them have died. By equipping these surviving cells with an engineered light-sensitive protein, the therapy effectively converts the retina’s output neurons into a substitute photoreceptor layer.

ChrimsonR alone is not enough, however. The protein responds to specific wavelengths of amber-red light, and ordinary ambient illumination is not structured in a way the modified cells can interpret usefully. To bridge that gap, participants wear specialized goggles with a built-in camera that captures the visual scene and sends the information to a portable processor. The processor converts the image into patterns of light at wavelengths designed to activate ChrimsonR, and a projector inside the goggles projects those patterns back onto the retina. The system can, for example, transform the image of a hand into a simplified pattern of light that stimulates the treated cells, allowing the brain to receive visual information through a completely rewired pathway.

On safety, the early-stage trial delivered encouraging results. Most eye-related side effects were mild or moderate, consisting mainly of temporary inflammation and short-lived increases in pressure inside the eye. No findings reported in the release suggested the therapy itself caused lasting harm, an important benchmark for a treatment that involves permanently introducing a new light-sensing protein into neural tissue. The researchers emphasize that this was a small, early-stage study, and that the treatment did not restore normal vision or the ability to read. Even so, some participants became better able to detect when an object was present, determine where it was located, and reach toward it accurately while using the goggles, functional abilities that can translate into greater independence in daily life.

The study went beyond behavioral testing to ask whether the new visual signals were actually reaching the brain. Using electroencephalography, a team led by Marlene Behrmann, professor of ophthalmology at Pitt, found evidence that visual signals reached and were processed by the visual cortex when participants viewed objects. That finding is scientifically striking, because it suggests that in people with profound, long-standing vision loss, the brain’s visual processing machinery remains intact and capable of interpreting input delivered through an entirely novel channel. Four participants showed consistent improvements across multiple real-world visual tasks over months to years of testing, indicating that the gains were not fleeting artifacts of a single laboratory session.

Sahel noted that the results demonstrate the visual system retains a remarkable capacity to process new information even after profound vision loss. He also pointed to the approach’s broader potential: because the strategy targets surviving retinal ganglion cells rather than any specific mutation, it could in principle help patients with other blinding diseases in which light-sensing cells have been lost but ganglion cells remain viable, a group that currently has few or no treatment options. That mutation-agnostic design is what distinguishes optogenetic therapy from the growing but still narrow portfolio of gene-specific treatments.

The new findings build directly on a landmark 2021 study published in Nature Medicine, which reported the first partial recovery of visual function in a blind patient following optogenetic therapy, the first clinical application of optogenetics in medicine. That work, carried out with longtime collaborator Botond Roska of the Institute of Molecular and Clinical Ophthalmology Basel, who is also a corresponding author of the current study, earned the two researchers the António Champalimaud Vision Award, the largest prize in the field, last month. The current trial was conducted as part of the PIONEER clinical study with support from GenSight Biologics, and included collaborators from Sorbonne Université, Institut de la Vision, and L’Hôpital Fondation Adolphe de Rothschild in Paris, the Institute of Molecular and Clinical Ophthalmology Basel and University of Basel in Switzerland, Streetlab in Paris, and Moorfields Eye Hospital in London.

The optogenetic program is one of several complementary strategies the Pittsburgh-led team is pursuing for end-stage retinal disease. Last year, Sahel was senior author of a New England Journal of Medicine paper describing vision restoration using an implanted prosthetic device, known as PRIMA, in patients with end-stage age-related macular degeneration. That technology has since received European Union authorization to be marketed for clinical use in many European countries. Together, the two approaches illustrate a shifting landscape in which blindness once considered irreversible is being reclassified as a engineering problem: if light-sensing cells are gone, the task becomes finding surviving neural tissue that can be repurposed to carry visual signals, whether by genetically reprogramming ganglion cells or by implanting a photovoltaic prosthetic. For the retinitis pigmentosa community, the new trial offers the strongest evidence yet that such repurposing can work safely in humans, while underscoring how much work remains before the therapy could move from a small trial toward approved, widely available treatment.

Subject of Research: Optogenetic gene therapy for restoring visual function in advanced retinitis pigmentosa

Article Title: Optogenetic therapy safe, shows signs of vision restoration in patients with advanced retinitis pigmentosa, according to international study led by Pitt scientists

Article References: Optogenetic therapy safe, shows signs of vision restoration in patients with advanced retinitis pigmentosa, according to international study led by Pitt scientists. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: optogenetics, retinitis pigmentosa, gene therapy, retinal ganglion cells, ChrimsonR, visual prosthesis, New England Journal of Medicine, University of Pittsburgh, vision restoration, clinical trial, retinal degeneration, visual cortex

The study, published in Cell Death Discovery by Lijun Zhang, Yan Li, and colleagues at Shandong Second Medical University, focuses on metallothionein 3, a small protein with a remarkable capacity to bind metal ions. The researchers set out to determine whether MT3 influences the development of RIRI by regulating a copper transport pathway known as the Atox1–ATP7a axis, thereby modulating cuproptosis, a form of regulated cell death that was only identified in recent years and had not previously been fully characterized in the context of retinal injury. The work combines transcriptomic sequencing, bioinformatic analysis, a rat model of retinal ischemia–reperfusion, cell culture experiments, recombinant protein rescue studies, and a battery of complementary molecular assays.

Cuproptosis entered the scientific vocabulary only recently, and its discovery reshaped how researchers think about metal-mediated cell death. Unlike apoptosis, necroptosis, or ferroptosis, cuproptosis depends directly on copper ions. In the canonical model, excess copper binds to lipid-acylated components of the mitochondrial tricarboxylic acid cycle, causing those proteins to aggregate. The result is a collapse of mitochondrial function, proteotoxic stress, and ultimately cell death. Because copper is an essential trace element that participates in respiration, antioxidant defense, and enzyme catalysis, cells must maintain it within narrow limits. Too little copper cripples metabolism; too much triggers the lethal aggregation that defines cuproptosis. Understanding how cells manage this delicate balance during disease has become a rapidly growing field.

The copper transport machinery at the center of the new study is a two-part system. Atox1, short for antioxidant 1 copper chaperone, is a small protein that ferries copper ions through the cell’s interior, delivering them to ATP7a, a copper-transporting adenosine triphosphatase embedded in cellular membranes. ATP7a then pumps copper out of the cell or routes it to copper-dependent enzymes. Together, this axis acts as a controlled export pathway, a molecular pump-and-chaperone system that keeps intracellular copper from accumulating to dangerous levels. When the axis falters, copper ions that should be expelled remain inside the cell, where they can participate in the protein aggregation and mitochondrial damage characteristic of cuproptosis.

Using their rat model of retinal ischemia–reperfusion injury, the researchers gathered evidence that cuproptosis occurs in retinal ganglion cells following RIRI. Retinal ganglion cells are the neurons whose long axons form the optic nerve, carrying visual signals from the eye to the brain. Their loss is irreversible, which is why ganglion cell death is the decisive event in glaucoma and many other blinding diseases. Demonstrating that this specific, copper-dependent death program operates in ganglion cells after ischemia–reperfusion adds an important new dimension to the cell death landscape of the retina, which researchers had previously mapped largely in terms of apoptosis and other better-studied pathways.

But the most striking finding concerned a different cell type. The researchers found that MT3 expression was markedly downregulated in retinal Müller cells, the glial cells that span the entire thickness of the retina and provide structural, metabolic, and homeostatic support to neurons. Müller cells are the workhorses of retinal maintenance: they regulate the chemical environment of the retina, buffer neurotransmitters, and help manage water and ion balance. The team found that this downregulation of MT3 was associated with impaired function of the Atox1–ATP7a copper transport axis, decreased copper ion efflux, and enhanced cuproptosis-related injury in Müller cells, ultimately exacerbating retinal damage. In other words, when MT3 levels fell, the copper export machinery weakened, copper accumulated, and the glial cells that support the retina suffered copper-driven injury.

To test whether this relationship was causal rather than merely correlational, the researchers turned to rescue experiments using recombinant MT3 protein. By supplying the protein experimentally, they could ask whether restoring MT3 function would protect cells from the cascade of copper accumulation and cuproptosis-related damage. Combined with their R28 retinal cell culture system and complementary molecular assays, these experiments allowed the team to build a mechanistic chain linking MT3, the Atox1–ATP7a axis, copper efflux, and cell survival. The study thereby explains, in mechanistic depth, how MT3 regulates cuproptosis through the Atox1–ATP7a axis in retinal ischemia–reperfusion injury.

The technical approach behind these conclusions reflects the modern toolkit of cell death research. Transcriptomic sequencing allowed the team to survey gene expression across the retina after injury, and bioinformatic analysis helped identify MT3 as a candidate regulator within the copper-handling network. The rat RIRI model, in which blood flow to the retina is temporarily interrupted and then restored, reproduces the ischemia–reperfusion conditions relevant to human ocular disease. R28 cells, a retinal precursor-derived cell line, provided a controlled in vitro environment for molecular manipulation, while recombinant MT3 protein enabled rescue experiments that tested the pathway’s function directly. Together, these complementary approaches strengthen the evidence that the MT3–Atox1–ATP7a–cuproptosis axis is a genuine regulatory circuit rather than an incidental association.

The clinical implications are significant. Because effective targeted therapeutic approaches for RIRI remain limited, the identification of MT3 as a regulator of copper-dependent injury suggests a promising novel therapeutic target. If MT3 levels could be preserved or restored in the retina after ischemic events, the copper export machinery might continue functioning, limiting cuproptosis-related damage to Müller cells and, by extension, reducing the secondary injury that spreads to vulnerable retinal ganglion cells. Such a strategy would represent a departure from current approaches that focus on lowering intraocular pressure or broadly suppressing inflammation, instead intervening at the level of a specific regulated cell death program and its metal-handling machinery.

The study also adds to a broader shift in biomedical science, in which cell death is understood not as a single failure mode but as a family of precisely regulated programs, each with its own triggers, molecular machinery, and therapeutic vulnerabilities. Copper, long appreciated mainly as an essential nutrient, has now been implicated as an active executioner in the retina under ischemic stress, with a specific chaperone-and-pump system serving as the gatekeeper. As researchers continue to map the roles of cuproptosis across tissues and diseases, the retina joins the growing list of organs in which metal ion homeostasis may prove to be the difference between recovery and irreversible damage. For the millions of people at risk of vision loss from retinal ischemia, that distinction could one day translate into new treatments built on a small copper-binding protein and the transport axis it controls.

Subject of Research: Regulation of cuproptosis by metallothionein 3 via the Atox1–ATP7a copper transport axis in retinal ischemia–reperfusion injury

Article Title: Metallothionein 3 regulates cuproptosis in rat retinal ischemia-reperfusion injury via the Atox1–ATP7a axis

Article References: Zhang, L., Li, Y., Liu, Z., Yu, F., Luo, J., Ci, R., Wang, X., & Zhao, Y. (2026). Metallothionein 3 regulates cuproptosis in rat retinal ischemia-reperfusion injury via the Atox1–ATP7a axis. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03386-3

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03386-3

Keywords: cuproptosis, metallothionein 3, retinal ischemia-reperfusion injury, Atox1, ATP7a, copper transport, retinal ganglion cells, Müller cells, cell death, retina, neuroprotection, glaucoma

The therapy takes a fundamentally different approach from conventional gene replacement treatments. Retinitis pigmentosa is an inherited disease in which the retina’s light-sensing cells, the photoreceptors, gradually lose their ability to respond to light, and mutations in more than 100 different genes can cause the condition. Because the genetic causes are so varied, treatments directed at any single genetic defect can only help a small fraction of patients. Optogenetic therapy sidesteps that problem entirely: instead of repairing a broken gene, it gives surviving retinal ganglion cells a new job. These cells, which normally relay signals from photoreceptors to the brain, are genetically reprogrammed to become light-sensitive themselves, effectively converting them into a substitute photoreceptor layer even at very advanced stages of blindness.

In the trial, each participant received a single injection into their worse-seeing eye carrying the genetic instructions for ChrimsonR, a light-sensitive protein derived from microbial opsins that responds to amber light. ChrimsonR was chosen for its spectral properties, since amber light is less likely to cause phototoxic damage than shorter wavelengths and can penetrate ocular tissue relatively well. The genetic payload prompts the ganglion cells to produce the protein in their membranes, so that when amber light strikes them, they depolarize and fire signals upward through the visual pathways. But the engineered cells respond only to light levels far brighter than ordinary ambient illumination, which is where the second component of the system comes in.

That component is a pair of special goggles equipped with a camera. The goggles capture the visual scene in front of the wearer and convert changes in that scene into pulses of amber light projected onto the treated retina, delivering the intensity and contrast that ChrimsonR requires to activate. Put simply, the gene therapy makes surviving retinal cells sensitive to light, and the goggles provide the light signal those cells need. The combination transforms the goggles into an artificial photoreceptor interface: the camera does the work that dead photoreceptors once did, and the reprogrammed ganglion cells pass the information along to the brain in a form the visual system can begin to interpret.

Safety was the primary endpoint of the study, a critical question for any therapy involving an injection into an eye that still retains some residual function. Within the limits of the study, the treatment was considered safe. Most eye-related adverse events were mild or moderate, and one severe event occurred immediately after injection but resolved within minutes after treatment. That favorable safety profile, combined with evidence of benefit, removes one of the biggest obstacles standing between optogenetics and wider clinical application, since any therapy that permanently alters retinal cells must first demonstrate that it does not endanger the eye it is meant to help.

The efficacy results were equally significant. Seven of the ten patients became more sensitive to light after treatment, and six of them reached the predefined threshold for a clinically meaningful improvement. Among the eight patients who completed visual behavioural testing, four improved in tasks such as detecting or locating objects. Even more patients improved in ecologically meaningful activities: finding a doorway in a room, or following a line on the floor while wearing the goggles. These are precisely the kinds of visual abilities that determine whether a person with profound vision loss can navigate independently, orient themselves in unfamiliar spaces, and move through daily life with greater confidence.

Objective confirmation came from measurements of brain activity. Imaging showed signals consistent with visual information actually reaching the visual areas of the brain in treated patients, indicating that the signals generated by the reprogrammed ganglion cells and delivered through the goggles were not merely artifacts of retinal stimulation but were being transmitted and processed along the normal visual pathways. For a therapy that works by co-opting cells that were never designed to be photoreceptors, this demonstration that the brain can receive and register the new input is a crucial piece of evidence that the approach taps into the residual architecture of the visual system.

One of the study’s most instructive findings concerns the role of rehabilitation. Training played an important part in the outcomes: patients who spent more time learning to use the goggles tended to perform better on object-detection tests. That pattern suggests that the brain requires practice to interpret the unfamiliar, pixelated signal arriving from the engineered ganglion cells, and that rehabilitation may be an essential component of optogenetic therapy rather than an optional add-on. The implication for future clinical practice is that successful treatment will likely involve not just an injection and a device, but a structured program of visual training that helps patients learn to make sense of their new input.

The researchers are careful about what the therapy does and does not achieve. The treatment did not restore normal sight, and the patients still could not read or recognize faces. The visual experience produced by the system is far coarser than natural vision, constrained by the resolution of the goggles, the properties of ChrimsonR, and the density of surviving ganglion cells. Yet the significance of the results lies elsewhere: the study demonstrates that even at a very advanced stage of blindness, when photoreceptors are long gone, surviving retinal ganglion cells can be made responsive to light and can transmit visual information to the brain. That principle, now validated in a cohort rather than a single patient, opens a therapeutic window that did not previously exist for this population.

Stefan Futterknecht, second author of the study, who played a major role in analyzing the data, captured the significance of the moment: “This study represents an important milestone for optogenetic vision restoration. It demonstrates that the effects first observed in a single patient can be reproduced across several patients and provides a foundation for developing more sensitive and effective future therapies.” The full article, “Optogenetic Therapy for Restoring Aspects of Visual Function,” appeared in the New England Journal of Medicine. The same international collaboration that performed the 2021 proof-of-concept study carried out this work, and the consistency between the two results strengthens confidence that optogenetic vision restoration is a reproducible clinical reality. The path forward, the researchers indicate, lies in developing more sensitive and effective optogenetic proteins, refining the goggles, and optimizing training protocols, so that the partial sight demonstrated in this cohort can be deepened and extended to more of the people waiting for it.

Subject of Research: Optogenetic gene therapy with light-stimulating goggles for restoring visual function in blind patients with advanced retinitis pigmentosa

Article Title: Optogenetic therapy is safe and allows blind people to detect objects

Article References: Optogenetic therapy is safe and allows blind people to detect objects. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: optogenetics, retinitis pigmentosa, gene therapy, ChrimsonR, retinal ganglion cells, vision restoration, clinical trial, New England Journal of Medicine, IOB Basel, photoreceptors, visual rehabilitation, blindness

Optic pathway gliomas are low-grade tumors that arise anywhere along the visual system, from the optic nerve behind the eye to the chiasm and the radiation of fibers carrying signals toward the visual cortex. They account for roughly three to five percent of all pediatric brain tumors and are most commonly pilocytic astrocytomas, slow-growing World Health Organization Grade I lesions with excellent overall survival. The catch is morbidity rather than mortality. A large share of affected children carry a diagnosis of neurofibromatosis type 1, and among children with this genetic condition, approximately fifteen to twenty percent will develop these tumors at some point. Progressive visual loss is the most common and most debilitating consequence, whether the tumor arises sporadically or in the setting of NF1, and it can profoundly disrupt a child’s neurodevelopment and quality of life.

Current therapy is aimed squarely at tumor control rather than at rescuing vision. Under established pediatric protocols, younger children typically receive chemotherapy while radiotherapy is generally reserved for those older than eight years. What has been missing is any disease-specific treatment for the visual dysfunction itself. The biological target that the Italian research team behind the new study focused on is the retinal ganglion cell, the neuron whose long axon forms the optic nerve. Children with optic pathway gliomas often show thinning of the retinal nerve fiber layer, the bundled axons of these cells, driven by apoptosis, a form of programmed cell death. In NF1-associated tumors, this cell death may stem not only from mechanical compression by the tumor mass but also from a functional deficit caused by loss of the neurofibromin protein, which triggers hyperactivation of the Ras signaling pathway, phosphorylation of atypical protein kinase C, and a drop in intracellular cyclic AMP. Crucially, work in rodent models has shown that ganglion cell apoptosis is preceded by a phase of axonal damage, opening a therapeutic window during which intervention might still prevent irreversible cell loss.

Nerve growth factor, the prototypical neurotrophin, has emerged as a leading candidate for exploiting that window. The molecule signals through two classes of receptors on cell surfaces: the high-affinity tyrosine kinase receptor TrkA and the low-affinity p75 neurotrophin receptor. Both are expressed throughout the visual system, from retina to cortex, and on retinal ganglion cells themselves, where endogenous NGF normally serves as a survival factor. Preclinical studies have repeatedly shown that supplying extra NGF can attenuate ganglion cell death after optic nerve injury, and more recent experiments with optic nerve crush models demonstrated that both recombinant human NGF injections and eye drop formulations can promote axonal regrowth, apparently by interfering with apoptotic machinery, including inhibition of the NogoA/p75NTR complex and suppression of Rho/ROCK2 signaling.

Those laboratory findings set the stage for the original clinical trial that the new report follows up. In that double-blind, randomized, placebo-controlled phase II study, eighteen children and young adults with optic pathway gliomas, aged between two and twenty-three years and with stable disease but severe visual impairment, were assigned to receive murine NGF as eye drops at a dose of 0.5 milligrams three times daily for ten consecutive days, or a matched placebo. The treatment course was strikingly short, yet it produced statistically significant improvements in electrophysiological measures of retinal and optic pathway function compared with placebo, along with a notable enlargement of the visual field in treated patients where reliable measurement was possible. No severe ocular or systemic adverse events were recorded, and MRI showed no tumor progression in either group.

The new publication extends that story to four years. Fifteen of the original eighteen participants, nine from the NGF arm and six from the placebo arm, agreed to continued clinical and neuroradiological monitoring, and importantly, no additional NGF, chemotherapy, or radiotherapy was given during the extended follow-up. Every six months the patients underwent general clinical and neuro-ophthalmological examinations, including visual acuity testing, Goldmann perimetry, flash visual evoked potentials, and the photopic negative response of the electroretinogram, a signal that specifically reflects the function of retinal ganglion cells. Brain MRI was performed annually and assessed by board-certified pediatric neuroradiologists using the Response Assessment in Neuro-Oncology criteria for low-grade glioma. Eleven of the fifteen patients had NF1, the median age at enrollment was 12.6 years, and most had previously received chemotherapy.

The headline result is stability. Comparing baseline and end-of-follow-up values, the researchers found no statistically significant change in median visual acuity, in the amplitude of visual evoked potentials, in the photopic negative response amplitude or timing, or in the radius of the visual field. At the level of individual eyes, only five of thirty showed any change in visual acuity over four years, and just three of those crossed the pre-specified threshold for clinical meaningfulness, a shift of at least 0.3 logMAR units, roughly fifteen letters on an eye chart. On imaging, stable disease was confirmed in all fifteen patients throughout the entire observation period. Two children showed minor tumor volume increases of about ten percent, but these fell short of the criteria for progressive disease and were not accompanied by clinical deterioration.

One intriguing wrinkle deserves attention. When the investigators re-analyzed individual visual field data, they found that the change from baseline differed significantly between the original treatment groups, both at three months and at the four-year endpoint: every patient originally assigned to NGF showed an increase or no change in visual field radius, while every placebo-assigned patient showed a decrease. Yet the authors are careful, and rightly so. Baseline visual field radius was itself substantially larger in the placebo group, a statistical imbalance that raises the specter of regression to the mean, and Goldmann perimetry is known to have within-visit test-retest variability that can approach twenty percent, with reliability that depends heavily on a child’s age and cooperation. The team explicitly labels any interpretation of a persistent treatment effect on the visual field as hypothesis-generating rather than confirmatory, a level of caution that stands out in a field often tempted by optimistic readings of small datasets.

Perhaps the most consequential question surrounding growth factor therapy in a tumor context is whether flooding the visual system with a pro-survival molecule might feed the neoplastic glial cells themselves. Here the evidence points the other way. Pediatric pilocytic astrocytomas characteristically downregulate TrkA, the receptor whose activation is associated with tumor cell proliferation, while upregulating the pro-apoptotic p75NTR receptor. Laboratory studies have shown that NGF inhibits the proliferation of rat glioma cells and drives them toward a more differentiated state, and more recent work demonstrated that ectopic NGF prevents proliferation in pediatric low-grade glioma cell lines by inducing cellular senescence. The four years of stable MRI scans in this cohort, spanning both treated and placebo patients, provide clinical reassurance consistent with that biology, although the authors note that the indolent natural history of these tumors is itself a plausible explanation for the observed stability.

The study’s limitations are acknowledged candidly. Fifteen patients is a small cohort, a consequence of the rarity of the condition and the pragmatic constraints of following up a completed trial, and the observational extension lacked the randomization that gave the original phase II study its power. Both eyes of most patients were included in analyses despite not being fully independent observations, and optical coherence tomography, a sensitive structural marker of ganglion cell integrity, could not be systematically repeated in young children for whom reliable scans often require sedation. What the study does establish is the sustained safety and tolerability of a short course of topical NGF in children, with no late ocular adverse events, no corneal sensitivity changes, and no evidence of tumor stimulation over four years. Whether nerve growth factor eye drops can genuinely preserve vision in children facing optic pathway glioma-related blindness will now depend on larger, adequately powered, prospective randomized trials with standardized outcome measures, for which this four-year safety record removes a significant barrier.

Subject of Research: Long-term safety and visual outcomes of topical nerve growth factor treatment in children with optic pathway gliomas

Article Title: Long-term outcomes after a randomized phase II trial of nerve growth factor eye drops for optic pathway gliomas: four-year follow-up findings in children

Article References: Ruggiero, A., Attinà, G., Placidi, G., D’Agostino, E., Amato, A., Verdolotti, T., Mastrangelo, S., & Falsini, B. (2026). Long-term outcomes after a randomized phase II trial of nerve growth factor eye drops for optic pathway gliomas: four-year follow-up findings in children. Journal of Neuro-Oncology, 179(2), Article 67. https://doi.org/10.1007/s11060-026-05777-z

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05777-z

Keywords: nerve growth factor, optic pathway glioma, neurofibromatosis type 1, pediatric neuro-oncology, retinal ganglion cells, neuroprotection, visual evoked potentials, pilocytic astrocytoma, eye drops, phase II trial, visual field, low-grade glioma

The research team, led by Ziyao Liu of the Second Affiliated Hospital of Xi’an Jiaotong University, began with a simple premise. Oxidative stress, the imbalance that lets reactive oxygen species overwhelm cellular antioxidant defenses, is a well-established contributor to optic nerve degeneration. But which of the hundreds of oxidation-related genes actually matter in POAG? To find out, the investigators assembled a comprehensive set of 885 oxidative stress-related genes from the GeneCards and MSigDB databases, then mined five public transcriptomic datasets from the Gene Expression Omnibus, using optic nerve head astrocyte samples from the GSE9963 cohort as their discovery set.

The screening pipeline was deliberately redundant. Weighted gene co-expression network analysis grouped genes into modules correlated with disease status, while two independent machine learning algorithms, LASSO regression and support vector machine recursive feature elimination, each flagged candidate genes under ten-fold cross-validation. When the three approaches were intersected, only two genes survived: FXN and CYP1B1. Of these, FXN proved the sharper diagnostic blade. Receiver operating characteristic analysis in the discovery cohort yielded an area under the curve of 0.945 for FXN, far exceeding CYP1B1’s 0.700, and the result held up across four independent validation datasets with AUC values ranging from 0.708 to 0.946.

A diagnostic meta-analysis pooling the five datasets strengthened the case further. Elevated FXN expression was significantly associated with POAG status, with an overall odds ratio of 6.35. Notably, FXN levels tracked with disease sample type but not with race, gender, or age, suggesting the signal reflects disease biology rather than demographic confounders. Bioinformatic characterization placed the protein in the cytosol and mitochondria, consistent with its known role in mitochondrial iron transport and respiration, and the team retrieved its three-dimensional structure from the AlphaFold database to support future drug design efforts.

The immune dimension added another layer of intrigue. CIBERSORT deconvolution showed that POAG samples with high FXN expression differed in estimated immune cell abundance, with M1 and M2 macrophage subtypes significantly reduced in the discovery cohort. Single-sample gene set enrichment analysis linked high FXN expression to signatures including antigen-presenting cell function, chemokine receptor interaction, and inflammation promotion, although these immune associations were less consistent across the validation cohorts. Metabolic profiling told a clearer story: gene set enrichment analysis repeatedly tied high FXN expression to glycolysis and pyruvate metabolism gene sets, hinting that FXN may participate in the metabolic reprogramming that accompanies glaucomatous degeneration.

Bioinformatics alone, however, could not establish causation. The team turned to an in vitro model in which retinal ganglion cell-derived R28 cells are injured by a 12-hour exposure to 200 micromolar hydrogen peroxide, a widely used simulation of oxidative stress injury in glaucoma research. Interestingly, while FXN was upregulated in patient tissue samples, hydrogen peroxide sharply decreased FXN expression in the cultured cells. That inverse response suggested a defensive role: the stressed cells were losing a protective factor. The researchers tested this by manipulating FXN with overexpression vectors and short hairpin RNAs, verifying the changes by quantitative PCR and western blot.

The functional assays were strikingly consistent. CCK8 and EdU assays showed that hydrogen peroxide suppressed cell survival, that FXN overexpression blunted this loss of viability, and that FXN knockdown made it worse. Flow cytometry using the BODIPY-C11 probe revealed that FXN overexpression significantly reduced the reactive oxygen species surge induced by peroxide treatment, while silencing FXN accelerated ROS accumulation. Annexin V staining and TUNEL assays confirmed the anti-apoptotic effect, with FXN overexpression defending cells against both early and late apoptosis. Western blots added a mechanistic clue: FXN overexpression increased levels of the antioxidant proteins NRF2, HO-1, and SOD1, while knockdown decreased them, indicating that frataxin bolsters the cell’s endogenous antioxidant defenses.

The deeper question was who controls FXN in the first place. Mining the hTFtarget and GeneCards databases produced four candidate transcription factors: MAX, YY1, RAD21, and CTCF. Cross-referencing public knockdown data from the KnockTF database and expression correlations in the discovery dataset narrowed the field, and PCR experiments in R28 cells delivered the verdict: only silencing CTCF downregulated FXN. CTCF, a zinc-finger protein famous for organizing chromatin into loops and insulating genes from inappropriate regulatory influences, emerged as the upstream switch. Chromatin immunoprecipitation sealed the argument, showing that CTCF antibody pulled down the FXN promoter sequence spanning bases 1797 to 1815 upstream of the transcription start site, one of four predicted binding sites.

The rescue experiments tied the axis together. CTCF expression itself dropped in the hydrogen peroxide model, mirroring FXN. Overexpressing CTCF preserved cell viability, reduced ROS accumulation, and curbed apoptosis just as FXN overexpression did, but when the researchers simultaneously knocked down FXN, much of that protection evaporated. In other words, CTCF shields retinal ganglion cells largely by switching on frataxin. Because CTCF is a global regulator, the team also intersected their 125 oxidative stress-related differentially expressed genes with predicted CTCF targets and found 79 overlaps, suggesting the CTCF-FXN axis may sit within a broader oxidative stress transcriptional network in POAG.

The authors are candid about the limitations. There is no animal model yet, the acute hydrogen peroxide model cannot fully reproduce the chronic oxidative environment of human glaucoma, and the regulatory mechanism still needs confirmation through promoter mutation assays and in vivo work. The immune findings require experimental validation, and whether FXN directly modulates mitochondrial ROS production remains open. Even so, the study delivers something glaucoma research has lacked: a biomarker with validated diagnostic performance across multiple cohorts, a plausible mechanistic story connecting oxidative stress, mitochondrial biology, and chromatin regulation, and a therapeutic hypothesis that could be tested. If frataxin’s protective power holds up in living retinae, the CTCF-FXN axis may become more than a molecular curiosity. It could become a target, and for a disease that currently can only be slowed, that would be a genuinely new frontier.

Subject of Research: The role of the CTCF-FXN regulatory axis in oxidative stress, diagnosis, and progression of primary open-angle glaucoma

Article Title: CTCF-FXN regulatory axis plays critical roles in clinical assessments and disease progression of primary open-angle glaucoma

Article References: Cai, D., Yu, Y., Ma, J., Li, T., & Liu, Z. (2026). CTCF-FXN regulatory axis plays critical roles in clinical assessments and disease progression of primary open-angle glaucoma. Journal of Molecular Medicine, 104(1), Article 114. https://doi.org/10.1007/s00109-026-02717-2

Image Credits: AI Generated

DOI: 10.1007/s00109-026-02717-2

Keywords: primary open-angle glaucoma, FXN, frataxin, CTCF, oxidative stress, retinal ganglion cells, reactive oxygen species, biomarker, transcriptional regulation, machine learning, mitochondria, neurodegeneration

The study, conducted in a mouse model of glaucoma, demonstrates that administration of rhNGF protects retinal ganglion cells from degeneration and preserves visual function. Crucially, the investigators did not stop at showing that the treatment worked; they dissected the mechanisms underlying the benefit, revealing that rhNGF counteracts two intertwined drivers of glaucomatous damage—oxidative stress and neuroinflammation. This dual action positions nerve growth factor not merely as a survival signal for ailing neurons, but as a molecular shield against the hostile retinal environment that develops as the disease progresses.

Nerve growth factor was the first neurotrophin ever discovered, identified more than seventy years ago by Rita Levi-Montalcini and Stanley Cohen, work that earned the Nobel Prize in Physiology or Medicine in 1986. NGF is best known for its role in the development and maintenance of sympathetic and sensory neurons, but it also acts on the central nervous system, including the retina, where its receptors—TrkA and p75NTR—are expressed by retinal ganglion cells and by glial cells such as Müller cells and astrocytes. Over the years, evidence has accumulated that NGF signaling can promote neuronal survival, yet translating that biology into a practical therapy has been difficult, in part because delivering protein drugs to target tissues is challenging and because earlier clinical efforts were hampered by formulation and delivery limitations.

In the glaucoma model used in the study, elevated intraocular pressure triggers a cascade of degenerative events in the retina. Pressure insult compromises axonal transport at the optic nerve head, deprives ganglion cells of trophic support, and sets off a vicious cycle in which stressed neurons release damage signals that activate glial cells. Activated microglia and macroglia, in turn, release pro-inflammatory cytokines such as TNF-alpha and interleukin-1 beta and generate reactive oxygen species, further injuring neurons and perpetuating the inflammatory loop. The result is progressive loss of retinal ganglion cells, thinning of the nerve fiber layer, and deterioration of the visual responses that these cells convey to the brain.

When the researchers administered rhNGF to the glaucomatous mice, they observed a marked preservation of retinal structure and function compared with untreated animals. Histological analysis revealed significantly higher survival of retinal ganglion cells, and functional assessments of the visual pathway confirmed that the anatomical protection translated into preserved vision-related output. The magnitude of the effect indicates that rhNGF does not merely delay degeneration marginally but provides substantive neuroprotection in this experimental setting.

The mechanistic findings are arguably the most significant contribution of the work. Molecular analyses of treated retinas showed a pronounced reduction in markers of oxidative stress. Levels of reactive oxygen species and lipid peroxidation products fell, while endogenous antioxidant defenses were bolstered. This matters because oxidative damage is now recognized as a central pillar of glaucoma pathobiology: the retina is one of the most oxygen-demanding tissues in the body, its ganglion cell mitochondria are exceptionally vulnerable, and oxidative modifications to proteins, lipids, and DNA accumulate early in the disease and correlate with neuronal loss. By damping oxidative injury, rhNGF appears to interrupt one of the key upstream triggers of the degenerative cascade.

Equally important was the effect on neuroinflammation. In untreated glaucomatous retinas, the researchers documented robust activation of microglia—the resident immune cells of the retina and optic nerve—along with elevated expression of inflammatory cytokines. In rhNGF-treated animals, microglial activation was substantially attenuated and the inflammatory signature was blunted. This anti-inflammatory action is notable because it suggests that NGF signaling, in addition to its classical trophic role, actively reprograms the glial response to injury. The TrkA receptor, when engaged by NGF, can activate survival pathways such as PI3K-Akt and MAPK signaling in neurons, while modulating the reactivity of glial cells that would otherwise amplify tissue damage. The study’s data indicate that both dimensions of NGF biology—direct neuronal support and immunomodulation—contribute to the observed protection.

The interplay between oxidative stress and inflammation is what makes these findings particularly compelling. These two processes are not independent; reactive oxygen species can activate inflammatory signaling pathways, including the NF-kappaB and inflammasome pathways, and inflammatory cells are themselves major producers of free radicals. In glaucoma, this creates a self-reinforcing spiral in which each process feeds the other. A therapy that targets only one arm of the spiral may achieve limited benefit, whereas an intervention that simultaneously reduces oxidative damage and suppresses neuroinflammation can potentially break the cycle. The rhNGF results suggest that the molecule does precisely that, which may explain why the neuroprotection achieved in the mouse model was so robust.

The therapeutic implications extend beyond the laboratory. Recombinant human NGF has already navigated part of the translational path: a topical ocular formulation of rhNGF has been approved in Europe for the treatment of neurotrophic keratitis, a disease of corneal nerve degeneration, providing clinical precedent for the safety and feasibility of delivering this protein to the eye. The new findings raise the prospect of repurposing or reformulating rhNGF for glaucoma, potentially as an adjunct to pressure-lowering therapy. Such a combination would address both sides of the disease: intraocular pressure as the major modifiable risk factor, and the downstream neurodegenerative processes that pressure control alone cannot fully halt. For the millions of patients who continue to progress despite adequate pressure management, a neuroprotective add-on would represent a genuine paradigm shift.

Significant work remains before rhNGF can be considered a glaucoma therapy. The current evidence comes from an animal model, and mouse glaucoma models, while informative, do not capture every feature of the human disease, which unfolds over decades rather than weeks. Questions of dosing, delivery route, treatment timing, and long-term safety will need to be answered, and results will need to be replicated in additional models and ultimately in clinical trials. Nevertheless, the study provides a rigorous mechanistic foundation for the idea that nerve growth factor can protect the optic nerve in glaucoma, and it identifies oxidative stress and neuroinflammation as tractable, druggable targets. If the neuroprotective efficacy observed in mice can be reproduced in patients, rhNGF could become one of the first treatments in ophthalmology to preserve vision not by lowering pressure, but by directly defending the neurons that make sight possible.

Subject of Research: Neuroprotective efficacy of recombinant human nerve growth factor in a mouse model of glaucoma

Article Title: rhNGF shows neuroprotective efficacy by counteracting oxidative stress and neuroinflammation in a glaucoma mouse model

Article References: Vecchiotti, D., Di Vito Nolfi, M., Compagnoni, C., Miscione, M. S., Verzella, D., D’Andrea, D., Flati, I., Galli, F., d’Angelo, M., Angelucci, A., Cattani, F., Cimini, A., Tessitore, A., Capece, D., Alesse, E., Allegretti, M., & Zazzeroni, F. (2026). rhNGF shows neuroprotective efficacy by counteracting oxidative stress and neuroinflammation in a glaucoma mouse model. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03345-y

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03345-y

Keywords: glaucoma, rhNGF, nerve growth factor, neuroprotection, oxidative stress, neuroinflammation, retinal ganglion cells, intraocular pressure, microglia, optic nerve, TrkA receptor, Cell Death Discovery

The answer to that question now appears to be a cautious yes, at least in animal models. When the project started, the fundamental goal was to create a material that could act as a wireless interface between light and living tissue, explains Menglin Chen, Associate Professor at the Department of Biological and Chemical Engineering at Aarhus University, who leads the research. The team can now show that the particles are able to activate nerve cells in blind retinas, which brings them closer to their long-term ambition of developing a new type of retinal prosthesis. Unlike electronic implants, which require surgical placement of metal and silicon devices, or gene therapies and optogenetic approaches, which require genetic modification of surviving retinal cells, the nanoparticles are simply injected and do their work without altering the genome of any cell. That difference could matter enormously for patients, because retinal degeneration has many different genetic causes and a treatment that works independently of the underlying mutation could, in principle, help far more people.

To understand why this matters, it helps to look at the biology of the back of the eye. The retina is a thin layer of tissue lining the interior of the eyeball, and its light-sensitive photoreceptors, the rods and cones, normally capture incoming photons and initiate the cascades of signaling that the brain interprets as vision. In retinitis pigmentosa, a hereditary disease that affects roughly one in a few thousand people worldwide, these photoreceptors gradually degenerate and die, leading to progressive tunnel vision and eventually blindness. Crucially, however, the photoreceptors are not the only cells in the retina. Other nerve cells, including the retinal ganglion cells that collect information from the entire retina and transmit it to the brain through the optic nerve, can remain intact and functional for years after the photoreceptors have been lost. The Danish-led team set out to exploit precisely this surviving neuronal infrastructure, creating a new connection between incoming light and the remaining nerve cells without genetically modifying them.

The nanoparticles themselves are made from graphitic carbon nitride, a light-sensitive semiconductor, and measure around 300 nanometres in diameter, small enough that they can be delivered by injection. They are hollow, and their carefully engineered structure makes them particularly effective at capturing visible light. The design draws inspiration in part from chloroplasts, the organelles that plants use to harvest energy from sunlight through photosynthesis. When the particles are exposed to light, they trigger a series of physical and chemical processes in their immediate surroundings, and those processes can influence signaling in living cells. The researchers have investigated this photomodulation effect across several biological scales, from single molecules and single cells up to whole animals, building an unusually comprehensive picture of how the material interacts with biology.

At the finest scale, using a precisely focused laser, the team was able to activate individual nanoparticles inside individual cells and trigger a signal that traveled through the stimulated cell and onward to its neighbors. At the tissue scale, in cardiac muscle cells, the researchers used ordinary LED light to influence the cells’ rhythm, making them beat more synchronously. That cardiac result demonstrates that the technology is not limited to the eye; the same light-to-cell interface could in principle be used to stimulate heart tissue or other electrically active cells. But it is the results in the eye that bring the technology closest to a specific medical application. The researchers injected the nanoparticles into the eyes of mice with advanced retinitis pigmentosa, where the particles accumulated on the surface of the retina, close to the retinal ganglion cells that relay visual information toward the brain. When the researchers illuminated the treated eyes, they detected activity in the visual cortex, and the mice changed their behavior in response to light. In isolated pig retinal tissue, LED light could likewise activate ganglion cells when the nanoparticles were present.

The researchers are careful about what these results do and do not mean. The experiments do not show that the team has restored normal vision in the mice. What they show is that the technology can generate a measurable biological response to light even when the photoreceptors that normally detect light have largely degenerated. Long-term safety and function remain to be studied in much greater detail before the technology could potentially be tested as a treatment in humans. Henri Leinonen, a retina specialist and co-author of the study, emphasizes the context: once the photoreceptors are lost, the options for restoring light sensitivity are still very limited, and each approach currently in development carries its own constraints. Gene therapies are mutation-specific, meaning a separate therapy is needed for each genetic defect. Optogenetics requires genetically modifying the surviving retinal cells so that they become light-sensitive. Electronic implants require invasive surgery to place electrodes inside or on the eye. That is why, he argues, it is worth testing strategies that work independently of the cause of the disease. What the study demonstrates, he says, is a light-evoked response in a degenerated retina, an early step rather than a finished prosthesis.

The new study also documents how dramatically the research project has evolved since it began. In 2019, Menglin Chen received a DKK 4.2 million Semper Ardens Accelerate grant from the Carlsberg Foundation for an idea then known as OptoMed. The aim was to develop light-sensitive nanomaterials that could be placed inside the body and stimulate cells wirelessly, without genetic modification. At that early stage, the researchers were investigating nanofibers and their potential to stimulate brain and heart cells. Since then, the team has continued to refine the technology and shifted its focus toward the hollow nanoparticles at the heart of the current work. Along the way, the researchers systematically studied how the particles absorb light, how they affect cellular signaling, how well cells tolerate them, and whether the effect also operates in intact tissue and in living animals. That progression is reflected in the scope of the new study: from activating a single nanoparticle inside a single cell, to synchronizing the beating of cardiac muscle cells, and ultimately to producing measurable light responses in blind mice.

The technology has also moved from fundamental research toward innovation. In 2024, the researchers filed an international patent application covering the technology, including the use of the nanoparticles as an injectable, light-activated retinal prosthesis and for stimulating cardiac cells. In 2025, Chen received a Pioneer Innovator Grant from the Novo Nordisk Foundation for a project called RetiNano: Biocompatible and injectable photovoltaic retinal prosthesis, which focuses specifically on developing the technology for use in the eye. Seven years ago, Chen notes, the team was working with a fundamental research idea; today it has preclinical results, an ongoing patent process and a concrete goal of developing the technology into a retinal prosthesis. There is still a long way to go before this could become a treatment for patients, but the researchers have reached a point where they can begin to ask very specific questions about what it will take to move the technology forward.

The coming years will therefore not simply be about demonstrating that the nanoparticles work. The team will need to improve the delivery route into the eye, document how the material behaves in the eye over longer periods, investigate its safety in greater depth, and continue developing the technology with a view to potential future clinical use. The research is led by Chen at Aarhus University in collaboration with Professor Bozhi Tian at the University of Chicago, Associate Professor Henri Leinonen at the University of Eastern Finland, Professor Thomas Corydon and Professor Yonglun Luo at the Department of Biomedicine at Aarhus University, Associate Professor Rasmus Schmidt Davidsen at the Department of Electrical and Computer Engineering at Aarhus University, Professor Mingdong Dong at the Department of Chemistry at Aarhus University, Professor Toke Bek at Aarhus University Hospital, and Professor Nikos Hatzakis at the University of Copenhagen. The work is now entering another new phase: moving from the question of whether microscopic solar cells can communicate with living cells at all, to whether the technology could one day help people who have lost their sight.

Subject of Research: Injectable light-sensitive nanoparticles for activating surviving retinal nerve cells in degenerated retinas as a new form of retinal prosthesis.

Article Title: Injectable nanoparticles make blind retinas respond to light

Article References: Injectable nanoparticles make blind retinas respond to light. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: retinal prosthesis, nanoparticles, graphitic carbon nitride, retinitis pigmentosa, Aarhus University, Nature Biomedical Engineering, photomodulation, blindness, retinal ganglion cells, optogenetics alternative, visual cortex, light-sensitive semiconductor

The central insight behind optogenetic therapy is elegantly simple. In advanced retinal degenerative diseases such as retinitis pigmentosa and end-stage age-related macular degeneration, the photoreceptors that normally convert light into electrical signals have degenerated, leaving the rest of the retinal circuitry largely intact but functionally dark. Conventional gene replacement therapy, which works by delivering a healthy copy of a single defective gene, is no longer applicable once the target cells are gone, particularly because these diseases can be caused by mutations in dozens of different genes. Optogenetics sidesteps this problem entirely: it is mutation-agnostic. By using viral vectors to deliver genes encoding light-sensitive proteins called opsins into whatever neurons remain, the therapy converts those cells into artificial photoreceptors capable of responding to light directly.

The technical foundation of the field was established in the mid-2000s, when researchers demonstrated that channelrhodopsin-2, a directly light-gated cation channel originally discovered in algae, could be expressed in neurons to control their activity with millisecond precision. Early proof-of-concept studies showed that ectopic expression of microbial-type rhodopsins could restore visual responses in mice with photoreceptor degeneration, and landmark work soon extended this approach to ON bipolar cells and to dormant cone photoreceptors in models of retinitis pigmentosa. What began as a neuroscience tool for controlling neural activity has since evolved into a therapeutic platform, with the retina emerging as arguably the most clinically advanced target for optogenetics in the entire human body.

One of the most consequential decisions in any optogenetic therapy is which retinal cell type to target. The review devotes detailed attention to this question, weighing the merits of retinal ganglion cells, bipolar cells, and residual cone photoreceptors. Ganglion cells, the output neurons of the retina, are readily accessible from the vitreous and survive late into degeneration, but targeting them means bypassing the retina’s internal image-processing circuitry entirely. Bipolar cells sit one synapse upstream and offer the possibility of preserving some of the retina’s native signal processing, potentially yielding better spatial resolution and more natural vision. Residual cones, even when metabolically compromised, can in principle be genetically reactivated and their existing downstream wiring exploited. Each strategy involves distinct trade-offs between accessibility, image fidelity, and light sensitivity, and no single approach has yet emerged as definitively superior.

Opsin engineering itself has progressed dramatically. First-generation tools such as channelrhodopsin-2 respond only to high-intensity blue light, far brighter than ambient levels, which is a fundamental problem for a therapy intended to work under everyday conditions. Subsequent generations have addressed this through several routes: microbial opsins with enhanced sensitivity, animal cone rhodopsins that exploit the retina’s natural biochemical amplification cascades, and engineered multicharacteristic opsins designed to combine fast kinetics, broad spectral sensitivity, and high responsiveness. Chimeric rhodopsins have shown highly sensitive visual restoration and even neuroprotective effects in mouse models, while rhodopsin-based approaches have demonstrated that enhanced sensitivity and adaptation can be achieved by recruiting the native phototransduction machinery. The review emphasizes that light sensitivity remains perhaps the single most important determinant of whether laboratory success translates into meaningful patient benefit.

Delivering these genes to the right cells presents its own formidable engineering challenge, and the review provides a thorough account of the viral vector platforms underpinning retinal gene delivery. Adeno-associated virus, or AAV, has become the workhorse of retinal gene therapy thanks to its safety profile, durability, and natural ocular tropism. Engineered capsids such as AAV7m8 and the directed-evolution variant AAV8BP2 have enabled efficient outer retinal gene delivery from a simple intravitreal injection, avoiding the surgical risks of subretinal administration. Yet AAV’s roughly 4.7-kilobase packaging limit constrains how large an opsin gene, promoter, and regulatory elements can be squeezed into a single vector. Creative solutions, including intein-mediated protein trans-splicing that splits large proteins across two vectors and reconstitutes them inside the target cell, are expanding what is possible, while cell-specific promoters drawn from retinal ganglion cell and bipolar cell biology sharpen targeting precision.

The clinical pipeline reflects this maturation. A watershed moment came in 2021, when researchers reported partial recovery of visual function in a blind patient with retinitis pigmentosa after optogenetic therapy using the opsin ChrimsonR combined with image-transmitting goggles, the first reported functional benefit in a human. Since then, multiple clinical trials have advanced worldwide, including studies of AAV-based RGS-optimized therapies, the STARLIGHT phase 2 trial of MCO-010 multicharacteristic opsin therapy in patients with Stargardt disease, and trials of programs including GS030, BS01, ZM-02 and RV-01 targeting advanced retinitis pigmentosa. Work in non-human primates has demonstrated high spatiotemporal resolution and pattern discrimination compatible with genuine vision restoration, providing critical evidence that the approach can scale from rodents to human-sized eyes.

Yet the review is notably candid about the barriers that remain. Interspecies differences loom large: the mouse retina, the workhorse of preclinical optogenetics, differs radically from the human retina in cell numbers, photoreceptor topography, and internal anatomy, meaning promising rodent results do not guarantee human efficacy. The primate eye poses additional physical barriers, including the internal limiting membrane and the vitreoretinal interface, which impede vector penetration from the vitreous. Immune responses represent another serious concern, both to AAV capsids, which many patients have already encountered naturally, and to the microbial opsin proteins themselves, which the human immune system may recognize as foreign. Neural remodeling in the degenerated retina further complicates matters, as surviving circuits rewire in ways that may distort or degrade the signals delivered by engineered photosensitivity.

Perhaps less appreciated, but equally consequential, are the drug-development and regulatory hurdles. Patients with profound visual impairment present unique challenges for clinical trial design, and the field currently lacks standardized, validated clinical endpoints for measuring meaningful visual improvement in people with end-stage retinal degeneration. Traditional visual acuity measures are largely useless at these levels of vision loss, forcing investigators to develop novel outcome measures, from light-perception tasks to mobility and object-recognition tests, and to work closely with regulatory agencies and patient advocacy groups to define what constitutes a clinically meaningful benefit in a rare-disease population.

The review concludes that addressing these barriers is essential to establishing optogenetics as a clinically viable therapeutic modality and to enabling next-generation vision restoration. The trajectory is nonetheless striking: in barely two decades, optogenetics has moved from millisecond optical control of neurons in a dish to a growing international clinical pipeline offering realistic hope to patients for whom no other treatment exists. As opsin sensitivity improves, engineered capsids deliver genes more safely and precisely, and clinical endpoints mature, the prospect of restoring useful vision to millions of people blinded by photoreceptor degeneration is shifting from speculative ambition to an achievable clinical goal, one light-sensitive cell at a time.

Subject of Research: Optogenetic gene therapy for restoring vision in advanced retinal degenerative diseases

Article Title: Optogenetic vision restoration: translational barriers and emerging therapeutic strategies

Article References: Nakada, N. (2026). Optogenetic vision restoration: translational barriers and emerging therapeutic strategies. Gene Therapy. https://doi.org/10.1038/s41434-026-00640-2

Image Credits: AI Generated

DOI: 10.1038/s41434-026-00640-2

Keywords: optogenetics, vision restoration, gene therapy, retinitis pigmentosa, retinal degeneration, opsins, adeno-associated virus, retinal ganglion cells, bipolar cells, photoreceptors, clinical trials, blindness